A Randomized, Double-blind, Multicenter Trial Comparing Efficacy and Safety of Imipenem/Cilastatin/Relebactam Versus Piperacillin/Tazobactam in Adults With Hospital-acquired or Ventilator-associated Bacterial Pneumonia (RESTORE-IMI 2 Study)

Ivan Titov(Ivano-Frankivsk National Medical University), Luke F. Chen(Merck & Co., Inc., Rahway, NJ, USA (United States)), Joan R. Butterton(Merck & Co., Inc., Rahway, NJ, USA (United States)), Richard G. Wunderink(Northwestern University), Jiejun Du(Merck & Co., Inc., Rahway, NJ, USA (United States)), Katherine Young(Merck & Co., Inc., Rahway, NJ, USA (United States)), Aileen David-Wang(Philippine General Hospital), Matthew L. Rizk(Merck & Co., Inc., Rahway, NJ, USA (United States)), Antoine Roquilly(Nantes Université), Maria C Losada(Merck & Co., Inc., Rahway, NJ, USA (United States)), Amanda Paschke(Merck & Co., Inc., Rahway, NJ, USA (United States)), Daniel González(University of North Carolina at Chapel Hill), Munjal Patel(Merck & Co., Inc., Rahway, NJ, USA (United States)), Michelle Brown(University Hospital of Zurich), Helen W. Boucher(Tufts Medical Center), Keith S. Kaye(Johnson University), Robert Tipping(Merck & Co., Inc., Rahway, NJ, USA (United States)), Nicholas A. Kartsonis(Merck & Co., Inc., Rahway, NJ, USA (United States))
Clinical Infectious Diseases
July 6, 2020
Cited by 232


Related Papers